作者: Emily A. McVey
DOI: 10.1007/978-1-4614-3473-3_3
关键词:
摘要: The fate of pharmaceuticals in the environment has been studied for more than 50 years, with presence and potential effects acknowledged shortly thereafter [1–5]. It gradually become apparent that risk assessments developed usual chemical contaminants cannot be applied carte blanche to pharmaceuticals, because they are highly active specific biological systems at low levels [6–9]. Therefore, when applying assessment models environmental regulators must take into account not only complexity entity protected (the ecosystem large) but also regulated article (pharmaceuticals).